eMBR Genomics

Executive Summary

eMBR Genomics is a privately held biotechnology company based in Cambridge, MA, focused on developing CRISPR-based genomic medicines for severe inherited genetic diseases. Founded in 2021, the company aims to overcome the key bottleneck in in vivo gene editing—safe and efficient delivery—by leveraging proprietary novel delivery technologies. eMBR's approach seeks to enable precise, durable, and potentially curative therapies that address the root cause of genetic disorders. While the company is in early stages with no disclosed pipeline or financial details, its focus on delivery innovation positions it in a competitive yet high-impact area of genomic medicine. Success in demonstrating effective in vivo delivery could unlock significant value and partnerships.

Upcoming Catalysts (preview)

• Q2 2026Release of initial in vivo proof-of-concept data for lead program60% success
• Q3 2026Partnership or licensing deal with large pharma for delivery technology40% success
• Q1 2027Completion of IND-enabling studies for lead candidate50% success